AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
156.89
+0.44 (0.28%)
At close: Aug 17, 2026, 4:00 PM EDT
156.95
+0.06 (0.04%)
After-hours: Aug 17, 2026, 7:52 PM EDT

AstraZeneca Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
10,44610,2257,0355,9553,288112
Depreciation & Amortization
5,6695,3924,9814,8515,1784,039
Other Amortization
236236200280292311
Loss (Gain) From Sale of Assets
-196-155-60-292-216-509
Asset Writedown & Restructuring Costs
5882431,6234562262,428
Loss (Gain) From Sale of Investments
------776
Loss (Gain) on Equity Investments
1272812564
Stock-Based Compensation
36636642-712745
Other Operating Activities
-1,617-602-1,095-1,146-2,749-1,772
Change in Accounts Receivable
-1,728-1,728-1,624-1,425-1,349-961
Change in Inventory
-755-755-131-6693,9411,577
Change in Accounts Payable
1,3461,3468622,3941,1651,405
Operating Cash Flow
13,70014,57511,86110,3459,8085,963
Operating Cash Flow Growth
2.32%22.88%14.65%5.47%64.48%24.25%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-3,032-2,810-1,924-1,361-1,091-1,091
Sale of Property, Plant & Equipment
15135513228213
Cash Acquisitions
-891-1,230-3,782-1,099-1,035-10,117
Sale (Purchase) of Intangibles
-4,418-2,959-2,539-2,126-1,033-522
Investment in Securities
-109-108-133-87-143605
Other Investing Activities
2842863434776054
Investing Cash Flow
-8,151-6,808-7,980-4,064-2,960-11,058

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-364-16174-
Long-Term Debt Issued
-156,4923,816-12,929
Total Debt Issued
2,9483796,4923,9777412,929
Short-Term Debt Repaid
---31---276
Long-Term Debt Repaid
--2,401-4,968-5,210-1,515-4,999
Total Debt Repaid
-4,836-2,401-4,999-5,210-1,515-5,275
Net Debt Issued (Repaid)
-1,888-2,0221,493-1,233-1,4417,654
Issuance of Common Stock
444038332929
Repurchase of Common Stock
-690-521-81---
Common Dividends Paid
-4,777-4,846-4,606-4,491-4,364-3,856
Other Financing Activities
-369-195-840-876-1,047-178
Financing Cash Flow
-7,680-7,544-3,996-6,567-6,8233,649

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-1746-93-60-80-62
Net Cash Flow
-2,148269-208-346-55-1,508

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
10,66811,7659,9378,9848,7174,872
Free Cash Flow Growth
-4.54%18.40%10.61%3.06%78.92%26.94%
Free Cash Flow Margin
17.38%20.03%18.38%19.61%19.66%13.02%
Free Cash Flow Per Share
6.837.536.365.755.593.41
Levered Free Cash Flow
4,9057,8658,4619,04012,485-1,845
Unlevered Free Cash Flow
5,6478,5819,2229,60212,843-1,608

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
1,3231,3161,3131,081849721
Cash Income Tax Paid
3,3472,8452,7502,3661,6231,743
Change in Working Capital
-1,804-1,137-8933003,7572,021
SEC Filings: 10-K · 10-Q